WO2012077932A3 - Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant - Google Patents

Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant Download PDF

Info

Publication number
WO2012077932A3
WO2012077932A3 PCT/KR2011/009224 KR2011009224W WO2012077932A3 WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3 KR 2011009224 W KR2011009224 W KR 2011009224W WO 2012077932 A3 WO2012077932 A3 WO 2012077932A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyridine derivative
same
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
Prior art date
Application number
PCT/KR2011/009224
Other languages
English (en)
Korean (ko)
Other versions
WO2012077932A2 (fr
Inventor
김명화
구일회
천광우
류동규
최정훈
김영하
조보영
박지선
이한창
김강전
김승현
Original Assignee
제일약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제일약품주식회사 filed Critical 제일약품주식회사
Publication of WO2012077932A2 publication Critical patent/WO2012077932A2/fr
Publication of WO2012077932A3 publication Critical patent/WO2012077932A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne un nouveau dérivé de pyrazole pyridine ou des sels de qualité pharmaceutique de celui-ci, leur procédé de production, et une composition pharmaceutique les contenant. Le nouveau dérivé de pyrazole pyridine selon la présente invention inhibe la GSK-3β, et peut être efficacement utilisé pour prévenir ou traiter les troubles liés à la démence, à la maladie d'Alzheimer, à la maladie de Parkinson, au parkinsonisme variante démence frontotemporale, au complexe Parkinson-démence de Guam, à la démence due au VIH, ou aux pathologies liées à des enchevêtrements neurofibrillaires.
PCT/KR2011/009224 2010-12-07 2011-11-30 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant WO2012077932A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100124391A KR20120063283A (ko) 2010-12-07 2010-12-07 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR10-2010-0124391 2010-12-07

Publications (2)

Publication Number Publication Date
WO2012077932A2 WO2012077932A2 (fr) 2012-06-14
WO2012077932A3 true WO2012077932A3 (fr) 2012-09-07

Family

ID=46207575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009224 WO2012077932A2 (fr) 2010-12-07 2011-11-30 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant

Country Status (2)

Country Link
KR (1) KR20120063283A (fr)
WO (1) WO2012077932A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487159A1 (fr) 2011-02-11 2012-08-15 MSD Oss B.V. Inhibiteurs du RORgammaT
WO2014026327A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2014026330A1 (fr) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés 3-aminocycloalkyles en tant qu'inhibiteurs de rorgammat et leurs utilisations
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
SI3152199T1 (sl) 2014-06-03 2018-12-31 Idorsia Pharmaceuticals Ltd Pirazolne spojine in njihova uporaba kot blokatorji kalcijevega kanala tipa T
US10246426B2 (en) 2014-09-15 2019-04-02 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
EP3368516B1 (fr) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. Composés pyrazoles bicycliques substitués en tant qu'inhibiteurs de rorgammat et leurs utilisations
AU2016344115A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
CN111995589B (zh) * 2015-11-10 2023-12-05 国立大学法人九州大学 2,5－二氰基－3,6－二卤代吡嗪的制造方法
KR102296653B1 (ko) 2016-12-16 2021-09-01 이도르시아 파마슈티컬스 리미티드 T-유형 칼슘 채널 차단제를 포함하는 약학 조합물
TWI808960B (zh) 2017-02-06 2023-07-21 瑞士商愛杜西亞製藥有限公司 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法
WO2022015938A1 (fr) * 2020-07-15 2022-01-20 Ifm Due, Inc. Composés et compositions pour traiter des états pathologiques associés à une activité de sting
JP2024502472A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CA3223223A1 (fr) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Inhibiteurs de cdk2
CN118126038B (zh) * 2024-05-08 2024-07-12 烟台大学 吡唑并吡啶类衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045949A1 (fr) * 2001-11-26 2003-06-05 Smithkline Beecham P.L.C. Derives de pyrazolopyridine
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2004013140A1 (fr) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Compositions pyrazole convenant comme inhibiteurs de gsk-3
WO2009145814A2 (fr) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
WO2010104306A2 (fr) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045949A1 (fr) * 2001-11-26 2003-06-05 Smithkline Beecham P.L.C. Derives de pyrazolopyridine
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
WO2004013140A1 (fr) * 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Compositions pyrazole convenant comme inhibiteurs de gsk-3
WO2009145814A2 (fr) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
WO2010104306A2 (fr) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Also Published As

Publication number Publication date
WO2012077932A2 (fr) 2012-06-14
KR20120063283A (ko) 2012-06-15

Similar Documents

Publication Publication Date Title
WO2012077932A3 (fr) Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
IN2012DN02968A (fr)
WO2017132432A8 (fr) Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2012080729A3 (fr) Inhibiteurs de caséine kinase 1δ (ck1δ)
IN2014DN03206A (fr)
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2009010407A (es) Derivados fluorados de deferiprona.
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
ZA201306833B (en) Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
MX2015000334A (es) Derivado de benzodioxol y metodo de preparacion y uso del mismo.
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
MX2015016539A (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol -3-il)bencenosulfonamida como modulador de nachr alfa 7.
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2011089576A3 (fr) Nouvelles compositions pour réduire la production de ass 42 et leur utilisation dans le traitement de la maladie d'alzheimer (ad)
WO2011094434A3 (fr) Dérivés de 7-azoniabicyclo[2.2.1]heptane, procédés de production, et utilisation pharmaceutiques de ceux-ci
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847604

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11847604

Country of ref document: EP

Kind code of ref document: A2